全文获取类型
收费全文 | 17906篇 |
免费 | 930篇 |
国内免费 | 175篇 |
专业分类
耳鼻咽喉 | 213篇 |
儿科学 | 349篇 |
妇产科学 | 377篇 |
基础医学 | 2045篇 |
口腔科学 | 651篇 |
临床医学 | 1384篇 |
内科学 | 4652篇 |
皮肤病学 | 225篇 |
神经病学 | 2001篇 |
特种医学 | 666篇 |
外科学 | 3022篇 |
综合类 | 40篇 |
一般理论 | 2篇 |
预防医学 | 732篇 |
眼科学 | 276篇 |
药学 | 932篇 |
中国医学 | 18篇 |
肿瘤学 | 1426篇 |
出版年
2024年 | 16篇 |
2023年 | 201篇 |
2022年 | 464篇 |
2021年 | 731篇 |
2020年 | 434篇 |
2019年 | 598篇 |
2018年 | 639篇 |
2017年 | 488篇 |
2016年 | 543篇 |
2015年 | 585篇 |
2014年 | 778篇 |
2013年 | 1033篇 |
2012年 | 1474篇 |
2011年 | 1526篇 |
2010年 | 814篇 |
2009年 | 780篇 |
2008年 | 1142篇 |
2007年 | 1148篇 |
2006年 | 974篇 |
2005年 | 958篇 |
2004年 | 916篇 |
2003年 | 720篇 |
2002年 | 670篇 |
2001年 | 111篇 |
2000年 | 84篇 |
1999年 | 94篇 |
1998年 | 145篇 |
1997年 | 124篇 |
1996年 | 94篇 |
1995年 | 80篇 |
1994年 | 80篇 |
1993年 | 61篇 |
1992年 | 66篇 |
1991年 | 39篇 |
1990年 | 53篇 |
1989年 | 40篇 |
1988年 | 30篇 |
1987年 | 29篇 |
1986年 | 29篇 |
1985年 | 19篇 |
1984年 | 30篇 |
1983年 | 25篇 |
1982年 | 26篇 |
1981年 | 18篇 |
1980年 | 24篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
A case of Rubinstein‐Taybi syndrome associated with growth hormone deficiency in childhood
下载免费PDF全文
![点击此处可从《Clinical endocrinology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
2.
3.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献4.
5.
6.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
7.
Rocco Spagnuolo Alessandro Corea Mariantonietta Blumetti Alessia Giovinazzo Massimiliano Serafino Caterina Pagliuso Raffaele Pagnotta Grazia Curto Cristina Cosco Vincenzo Cosco Rosellina Margherita Mancina Pietro Garieri Anna Papaleo Laura Grande Anna Barilaro Eugenio Garofalo Andrea Bruni Patrizia Doldo 《Journal of advanced nursing》2020,76(11):2993-3002
8.
Maria Ricci Agostino Chiaravalloti Alessandro Martorana Giacomo Koch Vincenzo De lucia Gaetano Barbagallo Orazio Schillaci 《Annals of nuclear medicine》2020,34(4):254-262
The aim of our study was to investigate the impact of the epsilon phenotype in brain glucose consumption in a population with Alzheimer’s disease. Statistical Parametric Mapping (SPM8) was used to investigate differences in brain glucose consumption (as detectable by means of 18F FDG-PET/CT) in the population examined. A total of 129 patients (72 females and 57 males) with a diagnosis of probable AD according to the NINCDS-ADRDA criteria underwent the PET/CT examination. The mean (SD) age of the patients was 70 (± 7) years; the mean Mini-Mental State Examination was 19(± 5.6). 59 expressed epsilon 4 phenotype (E4) and 70 expressed the epsilon 3 phenotype (E3). Cerebral spinal fluid amyloid, tau, and t-tau have been measured resulting equal to 367.4 (± 149.1), 584.7 (± 312.1), and 79.2(± 45.9) pg/ml, respectively. Patients with confirmed amyloid and Tau changes were classified as AD. Patients with amyloid changes but negative Tau, considered as high risk of AD, were classified as IAD. Age, sex, MMSE, scholarship, and CSF parameters were used as a covariate in the SPM analyses. We did not find significant differences in age, gender, and MMSE and CSF parameters among groups. In the analysis of the AD group as compared to AD-E3, AD-E4 subjects show a significant reduction of brain glucose consumption in inferior frontal gyrus bilaterally (BA 45, BA 47). In the analysis of the IAD group as compared to IAD-E3, IAD-E4 subjects show a significant reduction of brain glucose consumption in right in medial, middle, and superior frontal gyrus (BA10, BA11), and in left medial and middle frontal gyrus (BA10, BA11). The differences between IAD-E3 and AD-E3 and between IAD-E4 and AD-E4 (and vice versa analysis) resulted not significant. APO-e4 is related to a major involvement of the frontal cortex confirming its role of risk factor in AD, while APO-3 seems not related to a specific pattern, supporting the hypothesis of neutral/protective role in AD. 相似文献
9.